When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Ocular hypertension - Wikipedia

   en.wikipedia.org/wiki/Ocular_hypertension

   Ocular hypertension is treated with either medications (eye drops), surgery, or laser. Treatment, by lowering the intraocular pressure, may help decrease the risk of vision loss and damage to the eye from glaucoma. Treatment options include pressure-lowering 'antiglaucomatous' eye drops, surgery, and/or laser eye surgery. [4]

3. Intravitreal injection - Wikipedia

   en.wikipedia.org/wiki/Intravitreal_injection

   Intravitreal injection was first mentioned in a study in 1911, in which the injection of air was used to repair a detached retina. [6] [7] [8] There were also investigations evaluating intravitreal antibiotics injection using sulfanilamide and penicillin to treat endophthalmitis in the 1940s, yet due to the inconsistency of results and safety concerns, this form of drug delivery was only for ...

4. Macular edema - Wikipedia

   en.wikipedia.org/wiki/Macular_edema

   Macular edema occurs when fluid and protein deposits collect on or under the macula of the eye (a yellow central area of the retina) and causes it to thicken and swell . The swelling may distort a person's central vision , because the macula holds tightly packed cones that provide sharp, clear, central vision to enable a person to see detail ...

5. Intravitreal administration - Wikipedia

   en.wikipedia.org/wiki/Intravitreal_administration

   The number of injections tripled to 15,000 in 2002 when triamcinolone injections were first used to treat diabetic macular oedema. [2] [3] This use continued to drive an increase to 83,000 injections in 2004. [2] In 2005 bevacizumab and ranibizumab intravitreal injections for the treatment of wet-AMD caused a rise in injections to 252,000. [2]

6. Anti-VEGF - Wikipedia

   en.wikipedia.org/wiki/Anti-VEGF

   A 2014 Cochrane Systematic Review studied the effectiveness of ranibizumab and pegaptanib, on patients who have macular edema caused by central retinal vein occlusion. [5] Participants in both treatment groups showed improvement in visual acuity measures and a reduction in macular edema symptoms over six months.

7. Aflibercept - Wikipedia

   en.wikipedia.org/wiki/Aflibercept

   Common adverse effects of the eye formulation include conjunctival hemorrhage, eye pain, cataract, vitreous detachment, floaters, and ocular hypertension. [13]Aflibercept (Zaltrap) has adverse effects typical of anti-cancer drugs, such as reduced blood cell count (leukopenia, neutropenia, thrombocytopenia), gastrointestinal disorders like diarrhea and abdominal pain, and fatigue.